CClinicalTrials.gg
CompletedNCT03092050Updated Sep 6, 2022

Group Therapy for Depressed Dementia Caregivers

An interventional study of Guided Imagery and Mindfulness and Facilitated Discussion in Depression, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-09-06.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

Depression in family caregivers of relatives with Alzheimer's Disorder and related dementias is a serious public health problem. This is a randomized, controlled, single-blind pilot clinical trial of depressed caregivers, to determine the efficacy and mechanisms of group therapy for depressed dementia caregivers.

Read the detailed description

The trial was designed to measure clinical outcomes including depressive symptoms and other secondary outcomes of caregivers of persons living with dementia. It also included magnetic resonance imagery scanning at baseline (prior to study group) and post group to identify candidate mechanisms of effects.

Notes related to outcome measurement. On 05.10.2017 (prior to participant enrollment), all secondary outcomes were approved by the UCSF IRB #16-20163. It was noted in the IRB that the primary outcome timepoint was to be obtained 4 weeks after the first group session. Due to magnetic resonance imaging scanning scheduling constraints, which occurred at the same time as the 4 weeks visit, the outcome could not be exactly four weeks post the first group session but was collected approximately at this time.

On 05.10.2017 (prior to participant enrollment), three-month post group secondary outcomes were also approved.

02

Conditions studied

  • Depression

Browse trials for

03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's enrollment of 46 is below the median of 83 across 1,629 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Endorse clinically relevant baseline depressive symptoms Primary caregiver for a relative with dementia

Exclusion criteria

Exclusion Criteria:

Age \< 45 Meditation / guided imagery practice more than twice per week Ideas of harming relative with dementia Current violence towards relative with dementia Adult Protective Services report on file Primary psychiatric disorder other than unipolar major depression Cognitive impairment on the part of the caregiver (Mini Mental State Examination score less than 24) Unstable medical illness Planned surgery Active drug or alcohol abuse Inability to understand written and oral English.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Facilitated Discussion

    Weekly facilitated discussion for 4 weeks

    Behavioral: Facilitated Discussion

  • Experimental
    Guided Imagery and mindfulness

    Weekly guided imagery and mindfulness for 4 weeks

    Behavioral: Guided Imagery and Mindfulness

Interventions

  • BehavioralGuided Imagery and Mindfulness

    This is a behavioral intervention using guided imagery and mindfulness techniques.

  • BehavioralFacilitated Discussion

    This is a behavioral intervention that involves discussion and group support.

06

What researchers measure

Primary outcomes

  1. Depression symptoms

    Self reported depression symptoms (Quick Inventory of Depression Symptoms)

    Time frame: approximately 4 weeks post initial group session

Secondary outcomes

  1. Depression symptoms - moderate term

    Self reported depression symptoms

    Time frame: approximately 3 months post initial group session

  2. Depression symptoms - clinician rated

    Hamilton Depression Rating Scale

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  3. Caregiver burden

    Caregiver Burden Scale self rated questionnaire

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  4. Anxiety symptoms

    State Trait Anxiety Inventory - Trait

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  5. Mindfulness

    Five Factor Mindfulness Questionnaire

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  6. Positive and Negative Affect

    Positive and Negative Affect Scale

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  7. Well-Being

    Mental Health Continuum Short Form

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  8. Stress

    Perceived Stress Scale

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  9. Resilience

    Connors Davidson Resilience Scale

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

  10. Connectedness to Nature

    Connectedness to Nature Scale

    Time frame: approximately 4 weeks post initial group session and approximately 3 months post initial group session

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03092050
Lead sponsor
Massachusetts General Hospital
Collaborators
National Institute on Aging (NIA)
Responsible party
Felipe A Jain (Psychiatrist, Massachusetts General Hospital) — Principal investigator
First posted
Mar 27, 2017
Start date
Mar 1, 2017
Primary completion
Jun 30, 2019
Completion
Jun 30, 2019
Last update
Sep 6, 2022

Study contacts

Felipe Jain, MD
principal investigator · Massachusetts General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion